Skip to main content
. 2017 Apr 27;8(28):45345–45355. doi: 10.18632/oncotarget.17477

Figure 3. Performance of MIC-1 combining with other biomarkers in the detection of lung cancer in the training group.

Figure 3

(Left) ROC curves of four biomarker panel, MIC-1 alone, Cyfra21-1, CA125, CEA combination and Cyfra21-1, CA125, CEA, NSE combination for all lung cancer cases (N = 350) and controls (N = 350); (Right) ROC curves of four biomarker panel, MIC-1 alone, Cyfra21-1, CA125, CEA combination and Cyfra21-1, CA125, CEA, NSE combination for early-stage lung cancer cases (N = 155) and controls (N = 350).